P
ProHub
English 简体中文 繁體中文
BCG Hard Cost Reduction

BioPharma LOE

#Bio-Pharma
ProHub Comment

This case requires candidates to conduct external benchmarking, identify cost overruns through comparative analysis, and develop a targeted cost reduction strategy. The case emphasizes both quantitative analysis (comparing IT spend ratios across competitors) and qualitative judgment (assessing which functions are candidates for outsourcing vs. requiring in-house expertise).

Estimated Time 15 minutes
Difficulty Hard
Source Duke
50 / 100
Fuqua & Co. is a global BioPharma firm. In 2009, they acquired a smaller player, Kenan-Flagler Co., for $41B. The key driver was a breakthrough oncology drug, KeyChapel, the first of its kind to selectively target and kill cancer cells. The acquisition proved far more successful than anticipated. While Fuqua & Co. expected KeyChapel to generate about $10B in annual sales, the drug has grown to produce ~$40B annually, making Fuqua & Co. the second largest BioPharma company in the world. KeyChapel’s loss of exclusivity (LOE) is expected in January 2028. At that point, Fuqua & Co. projects a 50% drop in revenues, which would severely impact their business. The client is scrambling to prepare for this shift and has engaged us to help. They have asked us to evaluate how they can right size their operation.

Clarifying Information

  1. Business Model: Client sells KeyChapel, the only proven drug on the market that kills cancer cells, as well as an HPV vaccine that has seen shrinking market share domestically and abroad that accounts for 20% of revenues, and a few other drugs making up the remaining revenue.
  2. Objective: Client wants to benchmark their organizational health against their competitors and use this information to target areas for cost reductions. They want to reduce costs by $4.5B before the LOE for KeyChapel.